Previous close | 45.17 |
Open | 48.18 |
Bid | 44.32 x 100 |
Ask | 44.45 x 100 |
Day's range | 44.06 - 45.19 |
52-week range | 44.06 - 77.32 |
Volume | |
Avg. volume | 977,974 |
Market cap | 8.08B |
Beta (5Y monthly) | 0.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.94 |
Earnings date | 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 86.16 |
SOMERSET, N.J., April 22, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the European Commission (EC) has granted approval of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), have demonstrated disease progression on
SOMERSET, N.J., April 11, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.